Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 329: Phase I Trial of Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (STEMos1) With and Without ALFQ Adjuvant
NCT07111078Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of SteMos1 in influenza (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety and tolerability at 52 weeks. Started Aug 2025; status: recruiting.
02
Drugs
SteMos1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07111078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07111078.